Liver microbiota axis at the center of healthy aging

Liver microbiota axis at the center of healthy aging - LiLife

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020231

Enrollment

460

Registered

2020-02-07

Start date

2019-10-24

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K76.0 K75.8 C22.0 C22.1

Interventions

Group 1: Arm / phase 1: identification - Recruitment of patients with fatty liver and fatty liver-related diseases (obesity, diabetes mellitus, insulin resistance and neoplasia). - Systematic characte

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Signed patient informed consent or signed consent form by the supervisor.

Exclusion criteria

Exclusion criteria: • age <18 years • pregnancy • Lack of consent

Design outcomes

Primary

Measure	Time frame
Characterization of the liver-microbiota axis and identification of biomarkers and therapy targets. Phase 1: identification Analysis of the relationship between liver diseases and intestinal microbiota and identification of possible therapy targets. Phase 2: intervention Investigation of the influence of targeted physical activity on the microbiota and liver function in aging people. Phase 3: implementation Examination of the effects of fecal microbiota transplantation on the liver in C. difficile patients. Measuring times: Depending on the diseases and the study phase, the surveys are carried out at different times; for example after 0, 6, 12 and 18 months. methods: - Determination of liver status - Examination of the stool and saliva microbiome - Genetic analysis in the blood - miRNA expression measurements in blood and stool - Metatranscriptome analyzes in the stool - Metaproteome analysis in the stool	—

Measure

Time frame

Characterization of the liver-microbiota axis and identification of biomarkers and therapy targets. Phase 1: identification Analysis of the relationship between liver diseases and intestinal microbiota and identification of possible therapy targets. Phase 2: intervention Investigation of the influence of targeted physical activity on the microbiota and liver function in aging people. Phase 3: implementation Examination of the effects of fecal microbiota transplantation on the liver in C. difficile patients. Measuring times: Depending on the diseases and the study phase, the surveys are carried out at different times; for example after 0, 6, 12 and 18 months. methods: - Determination of liver status - Examination of the stool and saliva microbiome - Genetic analysis in the blood - miRNA expression measurements in blood and stool - Metatranscriptome analyzes in the stool - Metaproteome analysis in the stool

—

Countries

Germany

Contacts

Public ContactAlexander Link

Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie

alexander.link@med.ovgu.de+49-391-67-13106

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026